NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/24/2026
Back to search
Official data from USPTO
GC BIOPHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
44
Latest update
02/25/2026
Trademark type
Combined
Nice classes
5, 42
Filing date
03/07/2022
Registration date
02/24/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/24/2026
Last transaction
02/25/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
03/29/2022
First use in commerce
07/08/2024
Drawing code
3
Owner type
03
Owner location
Yongin-si, Gyeonggi-do, KR
Examiner
RINKER, ANTHONY MICHAEL
Law office
L20
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a stylized rounded cross with the top and right arms in red fading toward the middle to orange then to yellow, and the left and lower arms in green; to the right of the cross are the stylized wording "GC BIOPHARMA" in dark blue; the color white is not claimed as a feature of the mark and represents background and transparent areas only.
Holders and representatives
Holders
Green Cross Holdings Corporation
Representatives
Kwang Yup Chae HAUPTMAN HAM, LLP.
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medicines for humans used for the prevention and treatment of Immunodeficiency diseaseHuman Immunodeficiency Virusrare disease; Medicines for humansblood plasma-derivativesalbuminsimmunoglobulinsblood clotting factors; Biological preparations for medical or veterinary purposesbiological preparations used for the prevention and treatment of Immunodeficiency diseaseHuman Immunodeficiency Virusrare disease; Biological preparations for medical or veterinary purposesblood plasma-derivativesalbuminsimmunoglobulinsblood clotting factors
Class 42
Research and development of medicines; Research and developmentscientific research in the field of pharmaceuticalsblood plasma preparationsrecombinant proteins and antibodies; Scientific research in the fields of biomedicine; Research and development in the pharmaceutical and biotechnology fields
Publications
History of USPTO decisions and trademark events.
44 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
02/24/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
02/05/2026
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
02/05/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/05/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/05/2026
ALIE
ASSIGNED TO LIE
02/05/2026
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/29/2026
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/14/2025
GNRT
NON-FINAL ACTION E-MAILED
11/14/2025
CNRT
SU - NON-FINAL ACTION - WRITTEN
11/14/2025
SUPC
STATEMENT OF USE PROCESSING COMPLETE
10/10/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
10/10/2025
IUAF
USE AMENDMENT FILED
05/08/2025
EISU
TEAS STATEMENT OF USE RECEIVED
05/08/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
02/05/2025
EX4G
SOU EXTENSION 4 GRANTED
02/05/2025
EXT4
SOU EXTENSION 4 FILED
02/05/2025
EEXT
SOU TEAS EXTENSION RECEIVED
02/05/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
07/24/2024
EX3G
SOU EXTENSION 3 GRANTED
07/22/2024
EXT3
SOU EXTENSION 3 FILED
07/22/2024
EEXT
SOU TEAS EXTENSION RECEIVED
07/22/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
01/19/2024
EX2G
SOU EXTENSION 2 GRANTED
01/17/2024
EXT2
SOU EXTENSION 2 FILED
01/17/2024
EEXT
SOU TEAS EXTENSION RECEIVED
01/17/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/18/2023
EX1G
SOU EXTENSION 1 GRANTED
03/16/2023
EXT1
SOU EXTENSION 1 FILED
03/16/2023
EEXT
SOU TEAS EXTENSION RECEIVED
03/16/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
02/07/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/13/2022
PUBO
PUBLISHED FOR OPPOSITION
12/13/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/23/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/04/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
11/04/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/04/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
11/04/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/04/2022
DOCK
ASSIGNED TO EXAMINER
10/28/2022
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
03/12/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/11/2022
NWAP
NEW APPLICATION ENTERED
03/10/2022
Continuous trademark protection
Get notified about every new filing that threatens GC BIOPHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.